Form 4: Health Catalyst COO Sells Shares Under 10b5-1 Trading Plan

Daniel LeSueur, Chief Operating Officer of Health Catalyst, Inc., sold 5,209 shares of common stock at a price of $4.0951 per share on May 5, 2025, under a pre-arranged trading plan.

Summary

• On May 5, 2025, Daniel LeSueur, the Chief Operating Officer of Health Catalyst, Inc. (HCAT), sold 5,209 shares of the company's common stock.
• The sale was executed at a price of $4.0951 per share.
• Following the transaction, LeSueur directly owns 205,832 shares of Health Catalyst common stock.
• The sale was conducted under a pre-arranged trading plan adopted on March 7, 2024, in accordance with Rule 10b5-1.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some investors, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Health Catalyst, HCAT, Daniel LeSueur, Chief Operating Officer, stock sale, Form 4, 10b5-1 trading plan, insider trading